Antimüllerian hormone (AMH) and age as predictors of preimplantation genetic testing for aneuploidies (PGT-A) cycle outcomes and blastocyst quality on day 5 in women undergoing in vitro fertilization (IVF)

A Arnanz, A Bayram, I Elkhatib, A Abdala, A El-Damen, R Patel, B Lawrenz, L Melado, H Fatemi, N De Munck

Research output: Contribution to journalArticlepeer-review

8 Citations (Scopus)

Abstract

Purpose: The objective of this study was to investigate whether women with diminished ovarian reserve who planned for PGT-A exhibit a lower number of blastocysts for biopsy, ploidy outcomes, and blastocyst quality on day 5, regardless of age. Methods: A retrospective analysis was performed between March 2017 and July 2020 at ART Fertility Clinics Abu Dhabi, including couples that were triggered for final oocyte maturation in an ovarian stimulated cycle planned for PGT-A. Patients were stratified into four AMH groups: < 0.65 ng/ml, 0.65–1.29 ng/ml, 1.3–6.25 ng/ml, and > 6.25 ng/ml; four age categories: ≤ 30, 31–35, 36–40, and > 40 years. Main results and the role of chance: A total of 1410 couples with a mean maternal age of 35.2 ± 6.4 years and AMH of 2.7 ± 2.6 ng/ml were included. In a multivariate logistic regression analysis, controlling for age, the chance of having at least one blastocyst biopsied/stimulated cycle (1156/1410), the chance of having at least one euploid blastocyst/stimulated cycle (880/1410), and the chance of having one euploid blastocyst once biopsy was performed (880/1156) were affected in all patients with AMH < 0.65 ng/ml [AdjOR 0.18[0.11–0.31] p = 0.008)], [AdjOR 0.18 [0.11–0.29] p < 0.001], and [AdjOR 0.34 [0.19–0.61] p = 0.015] as well as in patients with AMH 0.65–1.29 ng/ml (AdjOR 0.52 [0.32–0.84] p < 0.001), (AdjOR 0.49 [0.33–0.72] p < 0.001), and (AdjOR 0.57 [0.36–0.90] p < 0.001), respectively. In a multivariate linear regression analysis, AMH values did not affect blastocyst quality (− 0.72 [− 1.03 to − 0.41] p < 0.001). Conclusion: Irrespective of age, patients with diminished ovarian reserve (AMH < 1.3 ng/ml) have a lower chance of having at least one blastocyst biopsied and lower chance of having at least one euploid blastocyst per ovarian stimulated cycle. Blastocyst quality was not affected by AMH values.

Original languageEnglish
Pages (from-to)1467-1477
Number of pages11
JournalJournal of Assisted Reproduction and Genetics
Volume40
Issue number6
DOIs
Publication statusPublished - Jun 2023

Bibliographical note

Funding Information:
We would like to thank Victor Lozoya for his initial support with data extraction and initial statistical evaluation.

Publisher Copyright:
© 2023, The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Keywords

  • Female
  • Pregnancy
  • Humans
  • Anti-Mullerian Hormone
  • Retrospective Studies
  • Fertilization in Vitro/methods
  • Genetic Testing
  • Aneuploidy
  • Blastocyst/pathology
  • Preimplantation Diagnosis/methods

Fingerprint

Dive into the research topics of 'Antimüllerian hormone (AMH) and age as predictors of preimplantation genetic testing for aneuploidies (PGT-A) cycle outcomes and blastocyst quality on day 5 in women undergoing in vitro fertilization (IVF)'. Together they form a unique fingerprint.

Cite this